A new approach to vocal cord leukoplakia and evaluation of proton pump ınhibitor treatment

  • Seda Sezen GoktasEmail author
  • Remzi Dogan
  • Alper Yenigun
  • Omer Faruk Calim
  • Orhan Ozturan
  • Selahattin Tugrul



Our aim is identify a new approach to vocal cord leukoplakia treatment and detect to efficiency of proton pump inhibitors.

Study design

Prospective, nonrandomized experimental clinical trial.


A ‘First Assessment Scale’ was prepared. This scale included the lesion’s and the patient’s characteristics. Using this scale, 24 patients included to the study. 20 mg rabeprazole twice daily was applied to all patients. At the end of 3rd month, a ‘Second Assessment Scale’ was used and two groups created. In group 1, 19 patients were accepted to responsive for the therapy and received the same therapy. The group 2 was included five patients that accepted unresponsive to treatment and directed to surgery. All patients received the same treatment additionally 3 months. At the end of 6th month, the Reflux Symptom Index (RSI), the Reflux Finding Score (RFS) and the Red–Green–Blue (RGB) values evaluated and comparisons were made.


The RSI and RFS values were significantly decreased in all patients. The Red values were significantly decreased with treatment in group 1, but the Green and Blue values were not. In group 2, the RGB values were not showed the significant differences. In conclusion, seven patients (29,2%) showed complete lesion regression, 12 patients (50%) showed partial lesion regression and five patients (20,8%) showed no response to treatment.


The proton pump inhibitor treatment may be beneficial for the selected patients. The scales that we prepared were useful for lesion assesment.


Vocal cord leukoplakia Laryngopharyngeal reflux Rabeprazole Proton pump inhibitor Leukoplakia Precancerous 



This study was not funded.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Durant G (1880) Case of cancer of the larynx. Arch Otolaryngol 1:61–62, 1880Google Scholar
  2. 2.
    Jackson C (1923) Cancer of the larynx: Is ıt preceded by a recognızable precancerous condıtıon? Ann Surg 77(1):1–14Google Scholar
  3. 3.
    Lee DH, Yoon TM, Lee JK, Lim SC (2015) Predictive factors of recurrence and malignant transformation in vocal cord leukoplakia. Eur Arch Otorhinolaryngol 272(7):1719–1724CrossRefGoogle Scholar
  4. 4.
    Fang T-J et al (2016) Classification of vocal fold leukoplakia by clinical scoring. Head Neck 38(S1):E1998–E2003CrossRefGoogle Scholar
  5. 5.
    Chen M, Cheng L, Li C-J, Chen J, Shu Y-L, Wu H-T (2017) Nonsurgical Treatment for Vocal Fold Leukoplakia: An Analysis of 178 Cases. Biomed Res Int 2017:6958250Google Scholar
  6. 6.
    Ricci G, Molini E, Faralli M, Simoncelli C (2003) Retrospective study on precancerous laryngeal lesions: long-term follow-up. Acta Otorhinolaryngol Ital 23(5):362–367Google Scholar
  7. 7.
    Zhu H, Xu W, Li Y, Cheng L (2014) Observation of clinicopathological characteristics of vocal fold leukoplakia and laryngopharyngeal reflux. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 49(5):368–373Google Scholar
  8. 8.
    Isenberg JS, Crozier DL, Dailey SH (2008) Institutional and comprehensive review of laryngeal leukoplakia. Ann Otol Rhinol Laryngol 117(1):74–79CrossRefGoogle Scholar
  9. 9.
    Wood JM, Hussey DJ, Woods CM, Watson DI, Carney AS (2011) Biomarkers and laryngopharyngeal reflux. J Laryngol Otol 125:1218–1224CrossRefGoogle Scholar
  10. 10.
    Feng G, Zhang Z, Diao C, Jiang J, Zheng S, Liu Y (2015) A bama minipig model of laryngopharyngeal reflux and the change of laryngopharyngeal mucosal ultrastructure. J Neurogastroenterol Motil 21(2):182–188CrossRefGoogle Scholar
  11. 11.
    Price JC, Jansen CJ, Johns ME (1990) Esophageal reflux and secondary malignant neoplasia at laryngoesophagectomy. Arch Otolaryngol Head Neck Surg 116:163–164CrossRefGoogle Scholar
  12. 12.
    Galli J et al (2002) The role of acid and alkaline reflux in laryngeal squamous cell carcinoma. Laryngoscope 112(10):1861–1865CrossRefGoogle Scholar
  13. 13.
    Galli J, Calo L, Agostino S, Cadoni G, Sergi B, Cianci R et al (2003) Bile reflux as possible risk factor in laryngopharyngealinflammatory and neoplastic lesions. Acta Otorhinolaryngol Ital 23:377–382Google Scholar
  14. 14.
    Gong X, Wang X-Y, Yang L, Sun M-J, Du J, Zhang W (2018) Detecting laryngopharyngeal reflux by immunohistochemistry of pepsin in the biopsies of vocal fold leukoplakia. J Voice 32(3):352–355CrossRefGoogle Scholar
  15. 15.
    Tan JJ et al (2016) The expression and significance of pepsin in laryngeal carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 51(8):593–599Google Scholar
  16. 16.
    Li X, Huang Z, Wu T, Wang L, Wu J (2014) Role of laryngopharyngeal reflux on the pathogenesis of vocal cord leukoplakia and early glottic cancer. Zhonghua Er Bi Yan Hou Ke Za Zhi 49(5):362–367Google Scholar
  17. 17.
    Copper MP, Smit CF, Stanojcic LD, Devriese PP, Schouwenburg PF, Mathus-Vliegen LMH (2000) High incidence of laryngopharyngeal reflux in patients with head and neck cancer. Laryngoscope 110(6):1007–1011CrossRefGoogle Scholar
  18. 18.
    Pierce NH (1920) Leucoplakia laryngis. Ann Otol Rhinol Laryngol 29(1):33–36CrossRefGoogle Scholar
  19. 19.
    Qadeer MA, Colabianchi N, Vaezi MF (2005) Is GERD a risk factor for laryngeal cancer? Laryngoscope 115(3):486–491CrossRefGoogle Scholar
  20. 20.
    Vaezi MF, Hicks DM, Abelson TI et al (2003) Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): a critical assessment of cause and effect association. Clin Gastroenterol Hepatol 1:333–344 2CrossRefGoogle Scholar
  21. 21.
    Rees CJ, Belafsky PC (2008) Laryngopharyngeal reflux: current concepts in pathophysiology, diagnosis, and treatment. Int J Speech Lang Pathol 10(4):245–253CrossRefGoogle Scholar
  22. 22.
    Lam PKY et al (2010) Rabeprazole is effective in treating laryngopharyngeal reflux in a randomized placebo-controlled trial. Clin Gastroenterol Hepatol 8(9):770–776CrossRefGoogle Scholar
  23. 23.
    Belafsky PC, Postma GN, Koufman JA, Patients B (2001) Laryngopharyngeal reflux symptoms improve before changes in physical findings. Laryngoscope 111:979–981CrossRefGoogle Scholar
  24. 24.
    Almadori G, Bussu F, Navarra P, Paludetti G, Giardina B, Maurizi M (2006) Pilot phase IIA study for evaluation of the efficacy of folic acid in the treatment of laryngeal leucoplakia. Cancer 107:328–336CrossRefGoogle Scholar
  25. 25.
    Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H et al (1999) Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 125:1083–1089CrossRefGoogle Scholar
  26. 26.
    et al. Xu J, Xue T, Bao Y (2014) Positive therapy of andrographolide in vocal fold leukoplakia. Am J Otolaryngol 35:77–84CrossRefGoogle Scholar
  27. 27.
    Gao X-W, Huang Y-W, Liu L-Y, Ouyang J (2016) Use videostrobokymography to quantitatively analyze the vibratory characteristics before and after conservative medical treatment of vocal fold leukoplakia. J Voice 30(2):215–220CrossRefGoogle Scholar
  28. 28.
    Simpson CB, Archilla AS, Velazquez RA, McGuff HS (2006) Resolution of vocal fold leukoplakia with proton-pump inhibitor therapy. Ear Nose Throat J 85:362–364Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Otorhinolaryngology ClinicBoyabat 75th State HospitalSinopTurkey
  2. 2.Department of Otorhinolaryngology, Faculty of MedicineBezmialem Vakif UniversityIstanbulTurkey

Personalised recommendations